Capricor Therapeutics, Inc. (CAPR) on Wednesday announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel for the treatment of Duchenne muscular dystrophy (DMD). The study met its primary endpoint, sending the company's shares up more than 14% in pre-market trading.
The trial randomized participants to receive either Deramiocel or a placebo over a 12-month period. Results showed clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy targeting Duchenne cardiomyopathy, the leading cause of mortality in DMD. The therapy maintained a favorable safety and tolerability profile, consistent with previous clinical experience.
Capricor plans to submit its response to the Complete Response Letter for Deramiocel's Biologics License Application (BLA) received in July, incorporating the HOPE-3 data, following prior alignment with the U.S. Food and Drug Administration.
Capricor Therapeutics shares had closed at $6.36, down 4.36% on Tuesday.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.